Why the study?
What are the perioperative 'MH-like' reactions associated with inhalational anesthetic agents in patients with Duchenne and Becker muscular dystrophy, and how can they be safely managed?
What are the perioperative 'MH-like' reactions associated with inhalational anesthetic agents in patients with Duchenne and Becker muscular dystrophy, and how can they be safely managed?
This review highlights the risk of acute rhabdomyolysis resembling malignant hyperthermia when using inhalational anesthetics in patients with Duchenne and Becker muscular dystrophy, providing recommendations for safe anesthetic management.
Answers are grounded in this paper and cite their sources.
May warrant caution with inhalational agents in Duchenne/Becker dystrophy; Level 5 reports leave open need for controlled safety studies.
Patients with Duchenne and Becker muscular dystrophy suffer from a progressive deterioration in muscle secondary to a defect in the dystrophin gene. As such, they are susceptible to perioperative respiratory, cardiac and other complications, such as rhabdomyolysis. Inhalational anesthetic agents have been implicated as a cause of acute rhabdomyolysis that can resemble malignant hyperthermia (MH). This article reviews perioperative 'MH-like' reactions reported in muscular dystrophy patients and groups them into three categories according to clinical presentation. The etiology and underlying pathophysiological process responsible for these reactions is discussed and recommendations are proposed for the safe anesthetic management of these patients.
No takes yet. Share an insight, caveat, or question.
Hayes et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: